公开(公告)号：US20100311755A1

公开(公告)日：2010-12-09

申请号：US12740714

申请日：2008-10-31

申请人： Wilfried Braje ,  Sean Colm Turner ,  Andreas Haupt ,  Udo Lange ,  Herve' Geneste ,  Karla Drescher ,  Liliane Unger ,  Ana Lucia Jongen-Relo ,  Anton Bespalov

发明人： Wilfried Braje ,  Sean Colm Turner ,  Andreas Haupt ,  Udo Lange ,  Herve' Geneste ,  Karla Drescher ,  Liliane Unger ,  Ana Lucia Jongen-Relo ,  Anton Bespalov

IPC分类号： A61K31/53 ,  C07D253/07 ,  A61P25/00 ,  A61P25/18 ,  A61P25/30 ,  A61P13/12

CPC分类号： C07D403/12

摘要： The invention relates to compounds of the formula I: wherein A is a saturated or unsaturated hydrocarbon chain having a chain length of 4 to 6 carbon atoms, the hydrocarbon chain being unsubstituted or substituted by 1, 2 or 3 methyl groups; R1 is selected from the group consisting of hydrogen, C1-C3 alkyl and fluorinated C1-C3 alkyl; R2 is hydrogen, halogen, cyano, C1-C3 alkyl, C1-C3 alkoxy, fluorinated C1-C3 alkyl or fluorinated C1-C3 alkoxy; R3 is selected from the group consisting of branched C4-C6 alkyl and C3-C6 cycloalkyl, and R4 is C1-C6 alkyl, C3-C6 cycloalkyl, fluorinated C1-C3-alkyl and fluorinated C3-C6 cycloalkyl. and the physiologically tolerated salts of these compounds and the N-oxides thereof. The invention also relates to a pharmaceutical composition that comprises at least one compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 agonists, said method comprising administering an effective amount of at least one compound or physiologically tolerated acid addition salt of the formula I to a subject in need thereof.

摘要翻译： 本发明涉及式I化合物：其中A是链长为4-6个碳原子的饱和或不饱和烃链，烃链未被取代或被1,2或3个甲基取代; R1选自氢，C1-C3烷基和氟化C1-C3烷基; R2是氢，卤素，氰基，C1-C3烷基，C1-C3烷氧基，氟化C1-C3烷基或氟化C1-C3烷氧基; R3选自支链C4-C6烷基和C3-C6环烷基，R4为C1-C6烷基，C3-C6环烷基，氟化C1-C3-烷基和氟化C3-C6环烷基。 以及这些化合物的生理上耐受的盐及其N-氧化物。 本发明还涉及包含至少一种式I化合物和/或其至少一种生理上耐受的酸加成盐的药物组合物，还涉及治疗有益于多巴胺D3受体拮抗剂或多巴胺D3的病症的方法 所述方法包括向有需要的受试者施用有效量的至少一种式I化合物或生理学上耐受的酸加成盐。

公开(公告)号：US20110319421A1

公开(公告)日：2011-12-29

申请号：US13187885

申请日：2011-07-21

申请人： Sean Colm Turner ,  Andreas Haupt ,  Wilfried Braje ,  Udo Lange ,  Karla Drescher ,  Liliane Unger ,  Ana Lucia Jongen-Relo ,  Anton Bespalov

发明人： Sean Colm Turner ,  Andreas Haupt ,  Wilfried Braje ,  Udo Lange ,  Karla Drescher ,  Liliane Unger ,  Ana Lucia Jongen-Relo ,  Anton Bespalov

IPC分类号： A61K31/496 ,  A61P3/10 ,  A61P25/18 ,  A61P25/30 ,  C07D401/04 ,  A61P25/00

CPC分类号： C07D401/04 ,  C07D213/76

摘要： The invention relates to compounds of the formula R1 is selected from the group consisting of hydrogen, linear C1-C3 alkyl and fluorinated linear C1-C3 alkyl; R2 is hydrogen or methyl; R3 is selected from the group consisting of hydrogen, halogen, C1-C2-alkyl, fluorinated C1-C2-alkyl, C1-C2-alkoxy and fluorinated C1-C2-alkoxy, R4 is C1-C2-alkyl or fluorinated C1-C2-alkyl; n is 0, 1 or 2, and the physiologically tolerated salts of these compounds and the N-oxides thereof. The invention also relates to a pharmaceutical composition that comprises at least one compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 agonists, said method comprising administering an effective amount of at least one compound or physiologically tolerated acid addition salt of the formula I to a subject in need thereof.

摘要翻译： 本发明涉及式R1的化合物选自氢，直链C 1 -C 3烷基和氟化线性C 1 -C 3烷基; R2是氢或甲基; R3选自氢，卤素，C1-C2-烷基，氟化C1-C2-烷基，C1-C2-烷氧基和氟化C1-C2-烷氧基，R4是C1-C2-烷基或氟化C1-C2 -烷基; n为0,1或2，以及这些化合物的生理上耐受的盐及其N-氧化物。 本发明还涉及包含至少一种式I化合物和/或其至少一种生理上耐受的酸加成盐的药物组合物，还涉及治疗有益于多巴胺D3受体拮抗剂或多巴胺D3的病症的方法 所述方法包括向有需要的受试者施用有效量的至少一种式I化合物或生理学上耐受的酸加成盐。

公开(公告)号：US08492540B2

公开(公告)日：2013-07-23

申请号：US12740714

申请日：2008-10-31

申请人： Wilfried Braje ,  Sean Colm Turner ,  Andreas Haupt ,  Udo Lange ,  Hervé Geneste ,  Karla Drescher ,  Liliane Unger ,  Ana Lucia Relo ,  Anton Bespalov

发明人： Wilfried Braje ,  Sean Colm Turner ,  Andreas Haupt ,  Udo Lange ,  Hervé Geneste ,  Karla Drescher ,  Liliane Unger ,  Ana Lucia Relo ,  Anton Bespalov

IPC分类号： C07D253/075 ,  C07D403/14 ,  A61K31/53 ,  A61P25/18 ,  A61P25/30 ,  A61P25/00

CPC分类号： C07D403/12

摘要： The invention relates to compounds of the formula I: wherein A is a saturated or unsaturated hydrocarbon chain having a chain length of 4 to 6 carbon atoms, the hydrocarbon chain being unsubstituted or substituted by 1, 2 or 3 methyl groups; R1 is selected from the group consisting of hydrogen, C1-C3 alkyl and fluorinated C1-C3 alkyl; R2 is hydrogen, halogen, cyano, C1-C3 alkyl, C1-C3 alkoxy, fluorinated C1-C3 alkyl or fluorinated C1-C3 alkoxy; R3 is selected from the group consisting of branched C4-C6 alkyl and C3-C6 cycloalkyl, and R4 is C1-C6 alkyl, C3-C6 cycloalkyl, fluorinated C1-C3-alkyl and fluorinated C3-C6 cycloalkyl. and the physiologically tolerated salts of these compounds and the N-oxides thereof. The invention also relates to a pharmaceutical composition that comprises at least one compound of the formula I and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine D3 receptor antagonists or dopamine D3 agonists, said method comprising administering an effective amount of at least one compound or physiologically tolerated acid addition salt of the formula I to a subject in need thereof.

摘要翻译： 本发明涉及式I化合物：其中A是链长为4-6个碳原子的饱和或不饱和烃链，烃链未被取代或被1,2或3个甲基取代; R1选自氢，C1-C3烷基和氟化C1-C3烷基; R2是氢，卤素，氰基，C1-C3烷基，C1-C3烷氧基，氟化C1-C3烷基或氟化C1-C3烷氧基; R3选自支链C4-C6烷基和C3-C6环烷基，R4为C1-C6烷基，C3-C6环烷基，氟化C1-C3-烷基和氟化C3-C6环烷基。 以及这些化合物的生理上耐受的盐及其N-氧化物。 本发明还涉及包含至少一种式I化合物和/或其至少一种生理上耐受的酸加成盐的药物组合物，还涉及治疗有益于多巴胺D3受体拮抗剂或多巴胺D3的病症的方法 所述方法包括向有需要的受试者施用有效量的至少一种式I化合物或生理学上耐受的酸加成盐。

公开(公告)号：US20090131452A1

公开(公告)日：2009-05-21

申请号：US12262455

申请日：2008-10-31

申请人： Wilfried Martin Braje ,  Sean Colm Turner ,  Andreas Haupt ,  Udo Lange ,  Karla Drescher ,  Karsten Wicke ,  Liliane Unger ,  Mario Mezler ,  Wolfgang Wernet ,  Matthias Mayrer ,  Ana Jongen-Relo ,  Anton Bespalov ,  Min Zhang

发明人： Wilfried Martin Braje ,  Sean Colm Turner ,  Andreas Haupt ,  Udo Lange ,  Karla Drescher ,  Karsten Wicke ,  Liliane Unger ,  Mario Mezler ,  Wolfgang Wernet ,  Matthias Mayrer ,  Ana Jongen-Relo ,  Anton Bespalov ,  Min Zhang

IPC分类号： A61K31/496 ,  C07D295/182 ,  C07D405/12 ,  A61P25/00 ,  A61K31/495

CPC分类号： C07D295/12 ,  C07D405/12

摘要： The present invention relates to novel benzenesulfonanilide compounds of the formulae I and I′ and physiologically tolerated acid addition salts and the N-oxides thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. wherein R1 is hydrogen or methyl R2 is hydrogen or methyl R3 hydrogen, fluorine C1-C2 alkoxy or fluorinated C1-C2 alkoxy; R4 is hydrogen, C1-C4 alkyl or fluorinated C1-C4 alkyl; R5 is hydrogen, fluorine, C1-C2 alkyl fluorinated C1-C2 alkyl C1-C2 alkoxy or fluorinated C1-C2 alkoxy; and R6 is hydrogen, fluorine or chlorine.

摘要翻译： 本发明涉及式I和I'的新型苯磺酰苯胺化合物和生理上耐受的酸加成盐及其N-氧化物。 该化合物具有有价值的治疗特性，特别适用于治疗对血清素5-HT 6受体调节作出反应的疾病。 其中R1是氢或甲基R2是氢或甲基R3氢，氟C1-C2烷氧基或氟化C1-C2烷氧基; R4是氢，C1-C4烷基或氟化C1-C4烷基; R5是氢，氟，C1-C2烷基氟化C1-C2烷基C1-C2烷氧基或氟化C1-C2烷氧基; R6是氢，氟或氯。

公开(公告)号：US20110086863A1

公开(公告)日：2011-04-14

申请号：US12851466

申请日：2010-08-05

申请人： Wilfried Martin Braje ,  Sean Colm Turner ,  Andreas Haupt ,  Udo Lange ,  Karla Drescher ,  Karsten Wicke ,  Liliane Unger ,  Mario Mezler ,  Wolfgang Wernet ,  Matthias Mayrer ,  Ana Jongen-Relo ,  Anton Bespalov ,  Min Zhang

发明人： Wilfried Martin Braje ,  Sean Colm Turner ,  Andreas Haupt ,  Udo Lange ,  Karla Drescher ,  Karsten Wicke ,  Liliane Unger ,  Mario Mezler ,  Wolfgang Wernet ,  Matthias Mayrer ,  Ana Jongen-Relo ,  Anton Bespalov ,  Min Zhang

IPC分类号： A61K31/496 ,  C07D241/04 ,  A61K31/495 ,  C07D405/12 ,  A61P25/00 ,  A61P3/04

CPC分类号： C07D295/12 ,  C07D405/12

摘要： The present invention relates to novel benzenesulfonanilide compounds of the formulae I and I′ and physiologically tolerated acid addition salts and the N-oxides thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. wherein R1 is hydrogen or methyl R2 is hydrogen or methyl R3 hydrogen, fluorine C1-C2 alkoxy or fluorinated C1-C2 alkoxy; R4 is hydrogen, C1-C4 alkyl or fluorinated C1-C4 alkyl; R5 is hydrogen, fluorine, C1-C2 alkyl, fluorinated C1-C2 alkyl, C1-C2 alkoxy or fluorinated C1-C2 alkoxy; and R6 is hydrogen, fluorine and chlorine.

摘要翻译： 本发明涉及式I和I'的新型苯磺酰苯胺化合物和生理上耐受的酸加成盐及其N-氧化物。 该化合物具有有价值的治疗特性，特别适用于治疗对血清素5-HT 6受体调节作出反应的疾病。 其中R1是氢或甲基R2是氢或甲基R3氢，氟C1-C2烷氧基或氟化C1-C2烷氧基; R4是氢，C1-C4烷基或氟化C1-C4烷基; R5是氢，氟，C1-C2烷基，氟化C1-C2烷基，C1-C2烷氧基或氟化C1-C2烷氧基; R6是氢，氟和氯。

公开(公告)号：US07790727B2

公开(公告)日：2010-09-07

申请号：US12262455

申请日：2008-10-31

申请人： Wilfried Martin Braje ,  Sean Colm Turner ,  Andreas Haupt ,  Udo Lange ,  Karla Drescher ,  Karsten Wicke ,  Liliane Unger ,  Mario Mezler ,  Wolfgang Wernet ,  Matthias Mayrer ,  Ana Jongen-Relo ,  Anton Bespalov ,  Min Zhang

发明人： Wilfried Martin Braje ,  Sean Colm Turner ,  Andreas Haupt ,  Udo Lange ,  Karla Drescher ,  Karsten Wicke ,  Liliane Unger ,  Mario Mezler ,  Wolfgang Wernet ,  Matthias Mayrer ,  Ana Jongen-Relo ,  Anton Bespalov ,  Min Zhang

IPC分类号： A61K31/495 ,  A61K31/496 ,  C07D295/135 ,  C07D317/62

CPC分类号： C07D295/12 ,  C07D405/12

摘要： The present invention relates to novel benzenesulfonanilide compounds of the formulae I and I′ and physiologically tolerated acid addition salts and the N-oxides thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. wherein R1 is hydrogen or methyl R2 is hydrogen or methyl R3 hydrogen, fluorine C1-C2 alkoxy or fluorinated C1-C2 alkoxy; R4 is hydrogen, C1-C4 alkyl or fluorinated C1-C4 alkyl; R5 is hydrogen, fluorine, C1-C2 alkyl, fluorinated C1-C2 alkyl, C1-C2 alkoxy or fluorinated C1-C2 alkoxy; and R6 is hydrogen, fluorine or chlorine.

摘要翻译： 本发明涉及式I和I'的新型苯磺酰苯胺化合物和生理上耐受的酸加成盐及其N-氧化物。 该化合物具有有价值的治疗特性，特别适用于治疗对血清素5-HT 6受体调节作出反应的疾病。 其中R1是氢或甲基R2是氢或甲基R3氢，氟C1-C2烷氧基或氟化C1-C2烷氧基; R4是氢，C1-C4烷基或氟化C1-C4烷基; R5是氢，氟，C1-C2烷基，氟化C1-C2烷基，C1-C2烷氧基或氟化C1-C2烷氧基; R6是氢，氟或氯。

公开(公告)号：US20130018047A1

公开(公告)日：2013-01-17

申请号：US13618865

申请日：2012-09-14

申请人： Andreas Haupt ,  Frauke Pohlki ,  Karla Drescher ,  Karsten Wicke ,  Liliane Unger ,  Ana-Lucia Relo ,  Anton Bespalov ,  Barbara Vogg ,  Gisela Backfisch ,  Juergen Delzer ,  Min Zhang ,  Yanbin Lao

发明人： Andreas Haupt ,  Frauke Pohlki ,  Karla Drescher ,  Karsten Wicke ,  Liliane Unger ,  Ana-Lucia Relo ,  Anton Bespalov ,  Barbara Vogg ,  Gisela Backfisch ,  Juergen Delzer ,  Min Zhang ,  Yanbin Lao

IPC分类号： A61K31/495 ,  A61K31/496 ,  A61P25/30 ,  A61K31/551

CPC分类号： C07D241/04 ,  C07D243/08 ,  C07D295/096 ,  C07D317/46

摘要： The present invention relates to N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating diseases that respond to modulation of the serotonin 5-HT6 receptor.

摘要翻译： 本发明涉及N-苯基 - （哌嗪基或高哌嗪基） - 苯磺酰胺或苯磺酰基 - 苯基 - （哌嗪或高哌嗪）化合物，含有它们的药物组合物及其在治疗中的用途。 该化合物具有有价值的治疗特性，特别适用于治疗对血清素5-HT6受体的调节作出反应的疾病。

公开(公告)号：US20100280014A1

公开(公告)日：2010-11-04

申请号：US12770837

申请日：2010-04-30

申请人： Andreas Haupt ,  Frauke Pohlki ,  Karla Drescher ,  Karsten Wicke ,  Liliane Unger ,  Ana-Lucia Relo ,  Anton Bespalov ,  Barbara Vogg ,  Gisela Backfisch ,  Juergen Delzer ,  Min Zhang ,  Yanbin Lao

发明人： Andreas Haupt ,  Frauke Pohlki ,  Karla Drescher ,  Karsten Wicke ,  Liliane Unger ,  Ana-Lucia Relo ,  Anton Bespalov ,  Barbara Vogg ,  Gisela Backfisch ,  Juergen Delzer ,  Min Zhang ,  Yanbin Lao

IPC分类号： A61K31/551 ,  C07D295/135 ,  C07D243/08 ,  C07D405/12 ,  A61K31/495 ,  A61P25/28 ,  A61P25/18 ,  A61P3/04 ,  A61P25/30 ,  A61K31/496

CPC分类号： C07D295/096 ,  C07D241/04 ,  C07D243/08 ,  C07D317/46

摘要： The present invention relates to N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. wherein X is a bond or a group N—R4; R1 is hydrogen or methyl; R2 is hydrogen or methyl; R3 is hydrogen, C1-C3 alkyl, fluorine, C1-C2 alkoxy or fluorinated C1-C2 alkoxy; R4 is hydrogen, C1-C4 alkyl, C3-C4 cycloalkyl, or C3-C4 cycloalkyl-CH2—; R5 is hydrogen, fluorine, chlorine, C1-C2 alkyl, fluorinated C1-C2 alkyl, C1-C2 alkoxy or fluorinated C1-C2 alkoxy; R6 is hydrogen, fluorine or chlorine; and n is 1 or 2.

摘要翻译： 本发明涉及N-苯基 - （哌嗪基或高哌嗪基） - 苯磺酰胺或苯磺酰基 - 苯基 - （哌嗪或高哌嗪）化合物，含有它们的药物组合物及其在治疗中的用途。 该化合物具有有价值的治疗特性，特别适用于治疗对血清素5-HT6受体的调节作出反应的疾病。 其中X为键或基团N-R4; R1是氢或甲基; R2是氢或甲基; R3是氢，C1-C3烷基，氟，C1-C2烷氧基或氟化C1-C2烷氧基; R4是氢，C1-C4烷基，C3-C4环烷基或C3-C4环烷基-CH2-; R5是氢，氟，氯，C1-C2烷基，氟化C1-C2烷基，C1-C2烷氧基或氟化C1-C2烷氧基; R6是氢，氟或氯; n为1或2。

公开(公告)号：US08362010B2

公开(公告)日：2013-01-29

申请号：US12769878

申请日：2010-04-29

申请人： Andreas Haupt ,  Frauke Pohlki ,  Karla Drescher ,  Karsten Wicke ,  Liliane Unger ,  Ana-Lucia Relo ,  Anton Bespalov ,  Barbara Vogg ,  Gisela Backfisch ,  Juergen Delzer ,  Min Zhang

发明人： Andreas Haupt ,  Frauke Pohlki ,  Karla Drescher ,  Karsten Wicke ,  Liliane Unger ,  Ana-Lucia Relo ,  Anton Bespalov ,  Barbara Vogg ,  Gisela Backfisch ,  Juergen Delzer ,  Min Zhang

IPC分类号： A61P3/04 ,  A61P25/18 ,  A61K31/551 ,  C07D243/08

CPC分类号： C07D243/08 ,  C07D405/12

摘要： The present invention relates to novel benzenesulfonanilide compounds of the formulae I and I′ and physiologically tolerated acid addition salts and the N-oxides thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. wherein R1 is hydrogen or methyl; R2 is hydrogen or methyl and is positioned vicinal to the radical R1; R3 hydrogen, C1-C3 alkyl, halogen, C1-C3 alkoxy, fluorinated C1-C3 alkyl or fluorinated C1-C3 alkoxy; R4 is hydrogen, C1-C4 alkyl, C3-C4 cycloalkyl, C3-C4 cycloalkylmethyl or fluorinated C1-C4 alkyl; R5 is hydrogen, fluorine, chlorine, C1-C4 alkyl, fluorinated C1-C4 alkyl, C1-C4 alkoxy or fluorinated C1-C4 alkoxy; and R6 is hydrogen, fluorine or chlorine.

摘要翻译： 本发明涉及式I和I'的新型苯磺酰苯胺化合物和生理上耐受的酸加成盐及其N-氧化物。 该化合物具有有价值的治疗特性，特别适用于治疗对血清素5-HT 6受体调节作出反应的疾病。 其中R1是氢或甲基; R2是氢或甲基，并且位于基团R1的邻近位置; R3氢，C1-C3烷基，卤素，C1-C3烷氧基，氟化C1-C3烷基或氟化C1-C3烷氧基; R4是氢，C1-C4烷基，C3-C4环烷基，C3-C4环烷基甲基或氟化C1-C4烷基; R5是氢，氟，氯，C1-C4烷基，氟化C1-C4烷基，C1-C4烷氧基或氟化C1-C4烷氧基; R6是氢，氟或氯。

公开(公告)号：US08076326B2

公开(公告)日：2011-12-13

申请号：US12770837

申请日：2010-04-30

申请人： Andreas Haupt ,  Frauke Pohlki ,  Karla Drescher ,  Karsten Wicke ,  Liliane Unger ,  Ana-Lucia Relo ,  Anton Bespalov ,  Barbara Vogg ,  Gisela Backfisch ,  Juergen Delzer ,  Min Zhang ,  Yanbin Lao

发明人： Andreas Haupt ,  Frauke Pohlki ,  Karla Drescher ,  Karsten Wicke ,  Liliane Unger ,  Ana-Lucia Relo ,  Anton Bespalov ,  Barbara Vogg ,  Gisela Backfisch ,  Juergen Delzer ,  Min Zhang ,  Yanbin Lao

IPC分类号： A61K31/495 ,  A61K31/496 ,  A61K31/551 ,  C07D295/112 ,  C07D317/64 ,  C07D317/66

CPC分类号： C07D295/096 ,  C07D241/04 ,  C07D243/08 ,  C07D317/46

摘要： The present invention relates to N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds, pharmaceutical compositions containing them, and their use in therapy. The compounds possess valuable therapeutic properties and are particularly suitable for treating diseases that respond to modulation of the serotonin 5-HT6 receptor. wherein X is a bond or a group N—R4; R1 is hydrogen or methyl; R2 is hydrogen or methyl; R3 is hydrogen, C1-C3 alkyl, fluorine, C1-C2 alkoxy or fluorinated C1-C2 alkoxy; R4 is hydrogen, C1-C4 alkyl, C3-C4 cycloalkyl, or C3-C4 cycloalkyl-CH2—; R5 is hydrogen, fluorine, chlorine, C1-C2 alkyl, fluorinated C1-C2 alkyl, C1-C2 alkoxy or fluorinated C1-C2 alkoxy; R6 is hydrogen, fluorine or chlorine; and n is 1 or 2.

摘要翻译： 本发明涉及N-苯基 - （哌嗪基或高哌嗪基） - 苯磺酰胺或苯磺酰基 - 苯基 - （哌嗪或高哌嗪）化合物，含有它们的药物组合物及其在治疗中的用途。 该化合物具有有价值的治疗特性，特别适用于治疗对血清素5-HT6受体的调节作出反应的疾病。 其中X为键或基团N-R4; R1是氢或甲基; R2是氢或甲基; R3是氢，C1-C3烷基，氟，C1-C2烷氧基或氟化C1-C2烷氧基; R4是氢，C1-C4烷基，C3-C4环烷基或C3-C4环烷基-CH2-; R5是氢，氟，氯，C1-C2烷基，氟化C1-C2烷基，C1-C2烷氧基或氟化C1-C2烷氧基; R6是氢，氟或氯; n为1或2。